High prevalence of hepatitis B virus infection in patients with aggressive B cell non-Hodgkin’s lymphoma in China

Wang, Chaoyu; Xia, Bing; Ning, Qiaoyang; Zhao, Haifeng; Yang, Hongliang; Zhao, Zhigang; Wang, Xiaofang; Wang, Yafei; Yu, Yonghao; Zhang, Yizhuo

doi:10.1007/s00277-017-3188-2

Cited by 28 publications

(33 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Because multiple myelomas are considered to be derived from terminally differentiated end‐stage B cells, it is rational to find an association between chronic hepatitis B and multiple myeloma. A case–control study by the Epilymph consortium showed that HBV infection increased the risk of multiple myeloma (OR: 1.97, 95% CI: 1.16‐3.37), and though this was confirmed using a meta‐analysis it has not been confirmed in other studies . Previous studies have failed to find a positive association between HBV infection and Hodgkin's lymphoma, though one recent meta‐analysis confirmed an association with Hodgkin's lymphoma .…”

Section: Discussionmentioning

confidence: 96%

“…Although a positive association between HBV and NHL was found in 1994, it has been less studied compared with HCV. Nevertheless, a few case–control studies have demonstrated the increasing prevalence of HBV infection (2.21‐3.67 fold) in patients with NHL in Korea, China, and Italy . However, a population‐based nested case–control study that used the Surveillance, Epidemiology, and End Results‐Medicare data in the United States and recent studies by the European Prospective Investigation into Cancer and Nutrition study, and the Epilymph consortium found no significant association between chronic hepatitis B infection and NHL.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Chronic hepatitis B is associated with an increased risk of B‐cell non‐Hodgkin's lymphoma and multiple myeloma

Liu

Tseng

et al. 2019

Aliment Pharmacol Ther

View full text Add to dashboard Cite

Background: Chronic hepatitis B has been linked to lymphoma with contradictory results.Aim: To investigate the association between chronic hepatitis B and lymphoma by using a nationwide population-based cohort. Methods: Records of patients diagnosed with chronic hepatitis B (hepatitis B virus[HBV] cohort) or without (non-HBV cohort) during 2004-2007 were retrieved from the Taiwan National Health Insurance Research Database. Age, sex, comorbidities, and medical visits were matched using propensity scores between both cohorts, and they were followed up longitudinally until 2012 to determine any new lymphoma development.Results: A total of 203 031 patients were included in each cohort with a mean follow-up of 7-9 years. The lymphoma incidence rate was significantly higher in the HBV cohort than in the non-HBV cohort (29.4 vs 15.9 per 100 000 person-years, P < 0.0001). After adjustment for comorbidities and medical visits, HBV infection was found to be an independent risk factor associated with the development of lymphoma (hazard ratio [HR]: 2.07, 95% confidence interval [CI]: 1.76-2.43, P < 0.0001) and non-Hodgkin's lymphoma (HR: 2.18, 95% CI: 1.80-2.65, P < 0.0001); specifically with an increased risk of diffuse large B-cell lymphoma (HR: 2.69, 95% CI: 2.05-3.52, P < 0.0001), other B-cell lymphoma (HR: 3.11, 95% CI:1.89-5.11, P < 0.0001), and also for multiple myeloma (HR: 1.63, 95% CI: 1.10-2.42, P = 0.016). The association was significant even after excluding lymphoma development within the first year (HR: 2.08, 95% CI: 1.75-2.47, P < 0.0001). Conclusions:Chronic hepatitis B is temporally associated with a 2-fold increased risk of lymphoma, particularly with B-cell non-Hodgkin's lymphoma, and also an increased risk for multiple myeloma.

show abstract

Section: Discussionmentioning

confidence: 96%

Section: Discussionmentioning

confidence: 99%

Chronic hepatitis B is associated with an increased risk of B‐cell non‐Hodgkin's lymphoma and multiple myeloma

Liu

Tseng

et al. 2019

Aliment Pharmacol Ther

View full text Add to dashboard Cite

show abstract

“…Complications of infection are one of the most severe risk factors that lead to death for leukemia patients. There have been comprehensive surveys for infections conducted in patients with malignancy including bacteria, virus and fungus (Mori et al, 2014; Vehreschild et al, 2014; Wang et al, 2017), but parasites, especially opportunistic infection parasites, in patients who are immunocompromised by virtue of neoplastic disease have received relatively little attention (Cong et al, 2015; Zueter et al, 2014).…”

Section: Introductionmentioning

confidence: 99%

Seroprevalence and risk factors of Toxoplasma gondii infection in children with leukemia in Shandong Province, Eastern China: a case—control prospective study

Zhou

Wang

et al. 2019

PeerJ

View full text Add to dashboard Cite

Limited information is available concerning the epidemiology of Toxoplasma gondii infection in children with leukemia in Eastern China. Therefore, a case-control study was conducted to estimate the seroprevalence of toxoplasmosis in this patient group and to identify risk factors and possible routes of infection. Serum samples were collected from 339 children with leukemia and 339 age matched health control subjects in Qingdao from September 2014 to March 2018. Enzyme linked immunoassays were used to screen anti- T. gondii IgG and anti- T. gondii IgM antibodies. Forty-eight (14.2%) children with leukemia and 31 (9.1%) control subjects were positive for anti-T. gondii IgG antibodies (P < 0.05), while 13 (3.8%) patients and 14 (4.1%) controls were positive for anti-T. gondii IgM antibodies (P = 0.84). Multivariate analysis showed exposure to soil and a history of blood transfusion were risk factors for T. gondii infection. Compared with IgG, patients with a history of blood transfusion were more likely to present anti- T. gondii IgM (P = 0.003). Moreover, patients with chronic lymphocytic leukemia and acute lymphocytic leukemia had higher T. gondii seroprevalence in comparison to control subjects (P = 0.002 and P = 0.016, respectively). The results indicated that the seroprevalence of T. gondii infection in children with leukemia is higher than that of healthy children in Eastern China. This information may be used to guide future research and clinical management, and further studies are necessary to elucidate the role of T. gondii in children with leukemia.

show abstract

“…In East Asia, chronic hepatitis B virus (HBV) infection is often seen in patients with malignancies including multiple myeloma. [ 1 2 3 ] There is a risk of reactivation of HBV during the treatment of various tumors including multiple myeloma. [ 4 5 ] With the emergence of new drugs, the treatment of multiple myeloma has now entered the era of targeted therapy from the era of traditional chemotherapy.…”

Section: Introductionmentioning

confidence: 99%

Clearance of HBsAg in a patient with familial multiple myeloma after a bortezomib-based regimen combined with anti-HBV drug

Zhang

Liang²,

Li³

et al. 2020

Medicine

View full text Add to dashboard Cite

Rationale: Reactivation of hepatitis B virus (HBV) after treatment with bortezomib-based regimens in HBV-positive patients with multiple myeloma (MM) has been reported in the past few years. Nevertheless, there is evidence of inhibition of HBV replication by bortezomib in transgenic mice. However, there is still no clinical evidence that bortezomib inhibits HBV. Patient concerns: A 55-year-old MM patient with a family history of MM, who was also a chronic HBV carrier, achieved HBV clearance after treatment with a bortezomib-based regimen in combination with anti-HBV drugs. Diagnoses: The diagnosis was MM with chronic carrier of HBV. Interventions: He received bortezomib-based regimen for MM as well as entecavir as a prophylaxis to prevent HBV reactivation. Outcomes: This patient achieved HBsAg and HBV-DNA clearance after 2 months and the remission was maintained during the next 2 years. He also achieved complete remission of MM and underwent consolidation therapy with autologous hematopoietic stem cell transplantation. Lessons: This is the first case of MM with HBV clearance after receiving a bortezomib-based regimen combined with anti-HBV drug. Research on related mechanisms might provide new suggestions and hope for better management of HBV positive patients with MM and for the treatment of HBV patients.

show abstract

High prevalence of hepatitis B virus infection in patients with aggressive B cell non-Hodgkin’s lymphoma in China

Cited by 28 publications

References 18 publications

Chronic hepatitis B is associated with an increased risk of B‐cell non‐Hodgkin's lymphoma and multiple myeloma

Chronic hepatitis B is associated with an increased risk of B‐cell non‐Hodgkin's lymphoma and multiple myeloma

Seroprevalence and risk factors of Toxoplasma gondii infection in children with leukemia in Shandong Province, Eastern China: a case—control prospective study

Clearance of HBsAg in a patient with familial multiple myeloma after a bortezomib-based regimen combined with anti-HBV drug

Contact Info

Product

Resources

About